Semaglutide for the Treatment of Obesity in Children 6 to
New England Journal of Medicine · 16.11.2026
DOI: 10.1056/nejmoa2604058 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, online erschienen am 16.11.2026. Verfasst von Ania M Jastreboff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Novo Nordisk.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to
Autor:innen und Institutionen
- Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT.
- Section of Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine, Yale University, New Haven, CT.
- Yale Obesity Research Center (Y-Weight), Yale School of Medicine, Yale University, New Haven, CT.
- Novo Nordisk, Søborg, Denmark.
- Department of Pediatrics, Yale School of Medicine, Yale University, New Haven, CT.
- University Hospital for Children and Adolescents, Center for Pediatric Research and Helmholtz Institute for Metabolic, Obesity, and Vascular Research (HI-MAG) of Helmholtz Munich at Leipzig University and Leipzig Univer…
ORCID-Profile: Ania M Jastreboff, Antje Körner, Martin Wabitsch
Förderung
- Novo Nordisk
Zitieren
APA
Jastreboff, A. M., Harder-Lauridsen, N. M., Van Name, M., Körner, A., Kelly, A. S., Weghuber, D., Holm, J. C., Frithioff-Bøjsøe, C., Middolu, S., Buch, T., Wabitsch, M., & STEP Young Investigators (2026). Semaglutide for the Treatment of Obesity in Children 6 to. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2604058
Vancouver
Jastreboff AM, Harder-Lauridsen NM, Van Name M, Körner A, Kelly AS, Weghuber D, et al. Semaglutide for the Treatment of Obesity in Children 6 to. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2604058
BibTeX
@article{Jastreboff2026,
author = {Jastreboff, Ania M and Harder-Lauridsen, Nina M and Van Name, Michelle and Körner, Antje and Kelly, Aaron S and Weghuber, Daniel and Holm, Jens-Christian and Frithioff-Bøjsøe, Christine and Middolu, Shilpa and Buch, Tina and Wabitsch, Martin and STEP Young Investigators, STEP Young Investigators},
title = {Semaglutide for the Treatment of Obesity in Children 6 to},
journal = {New England Journal of Medicine},
year = {2026},
doi = {10.1056/nejmoa2604058}
}
EUVIMED